Evidence map›Paper›PMID 35851754›Full record

ArticleCNS neuroscience & therapeutics2022

Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single-center, single-arm, open-label study.

Jie Ding, Xianguo Jiang, Yu Cai, Shuting Pan, Ye Deng, Meichun Gao, Yan Lin, Nan Zhao, Ze Wang, Haojun Yu and 8 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Telitacicept Inhibits the Maturation and Differentiation of B Lymphocytes in NMOSD.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Advances in the treatment of neuromyelitis optic spectrum disorder.Therapeutic advances in neurological disorders · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Jie DingDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.ORCID 0000-0002-0016-1141
Xianguo JiangDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Yu CaiDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Shuting PanClinical Research Center, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Ye DengDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Meichun GaoDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.ORCID 0000-0002-9921-9760
Yan LinDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Nan ZhaoDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Ze WangDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Haojun YuDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Huiying QiuDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Yuyan JinDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Jiahui XueDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Quan GuoDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Liping NiDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Ying ZhangDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Yong HaoDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.ORCID 0000-0003-3652-0449
Yangtai GuanDepartment of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Renji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNeuromyelitis optica spectrum disorders (NMOSD), mainly mediated by B cells and AQP4 antibody, has a high rate of recurrence. Telitacicept is a novel drug specifically targeting the upstream signaling for the activation of B cell with its following production of autoimmune antibodies. Thus, it may be a promising approach. Our study preliminarily explored the potential safety and effectiveness of Telitacicept following plasma exchange in the treatment of recurrent NMOSD.

methodsThis was a single-center, single-arm, open-label study enrolling eight patients with recurrent NMOSD in China. All patients received plasma exchange three times, followed by Telitacicept 240 mg every week for 46 times. The primary endpoint was the time of first recurrence after enrollment. Secondary end points included: changes in Expanded Disability Status Scale score, Optic Spinal Impairment Scale score, Hauser Ambulation Index, number of lesions on MRI, retinal nerve fiber layer thickness measured by optical coherence tomography, latency and amplitude of visual evoked potential, titer of AQP4 antibody, and immune parameters of blood. Safety was also assessed. The study was registered with Chictr.org.cn (ChiCTR1800019427).

resultsEight eligible patients were enrolled. Relapse occurred in two patients (25%) and five patients (63%) remained relapse free after 48 weeks of treatment. The time to first recurrence was prolonged and the number of recurrences was reduced (p < 0.001, power of test = 1). One patient withdrew from the study due to low neutrophil count. No serious adverse events occurred.

conclusionsIn this small, uncontrolled study, Telitacicept following plasma exchange has the potential to be a safe treatment for patients with recurrent NMOSD. It may prolong the recurrence interval and reduces the annual count of recurrences. A multicenter randomized controlled study with a larger sample is thus feasible and needed to further assess its safety and efficacy.

Indexed as

Neuromyelitis OpticaAquaporin 4AutoantibodiesEvoked Potentials, VisualHumansImmunosuppressive AgentsPlasma ExchangeRecurrenceRetinaAQP4 protein, humanAquaporin 4AutoantibodiesImmunosuppressive Agentsclinical studyeffectivenessneuromyelitis optica spectrum disordersplasma exchangesafetyTelitacicept

Identifiers

PMID35851754
PMCPMC9437241
OpenAlexW4286229676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.